Navigating Obesity Treatment Risks

This chapter explores recent advancements in obesity treatments, particularly focusing on Corbus Pharmaceuticals and its collaboration with Novo on cannabinoid receptor inhibitors. The discussion highlights the balance of risks and rewards in developing new drugs following a controversial history, while also addressing market responses and trial outcomes.